$MRNA #GateStockInsightsChallenge

Moderna's mRNA Cancer Vaccine Achieves Historic Success

Moderna and Merck's personalized mRNA cancer vaccine, intismeran, has achieved success in Phase 3 clinical trials. This marks a first for an mRNA cancer vaccine to yield positive results in a large-scale late-stage trial.

The companies announced Wednesday that intismeran, in combination with Merck's immune checkpoint inhibitor Keytruda, significantly slowed cancer recurrence and spread to other parts of the body in patients with high-risk melanoma (skin cancer). The Phase 3 INTerpath-001 trial involved 1,137 patients who had undergone surgical removal of tumors. Two-thirds of participants received the combination of intismeran and Keytruda, while one-third received Keytruda alone. The results showed statistically significant and clinically relevant improvements in recurrence-free survival (the primary goal of the trial) and distant metastasis-free survival (the secondary goal) compared to Keytruda. Previous Phase 2 data had shown the combination reduced the risk of relapse or death by 49%, and the risk of distant metastasis by 59%.

This success was met with a sharp rise in the stock market. Moderna shares gained 177% in the regular trading session, closing at $174.88 and reaching a market capitalization of $69.81 billion. In after-hours trading, shares rose another 6%, reaching around $185. Merck shares also gained approximately 12.6%.

Leerink Partners analyst Daina Graybosch predicts that intismera could become a blockchain drug with average revenue of $1.4 billion by 2032, while Barclays forecasts sales could reach $3 billion by 2035. Other analysts suggest that annual sales in melanoma alone could exceed $6 billion, and that this figure could rise much higher if the same approach works for lung, kidney, and bladder cancers. William Blair analysts stated that this success is critical for Moderna's revenue diversification from COVID-19 vaccines and justifies the "Outperform" rating given to the stock.

The treatment is tailored specifically to each patient's tumor. A tumor sample is analyzed to identify patient-specific neoantigens (proteins resulting from tumor mutations). Intismeran contains mRNA instructions for the body to produce these neoantigens. Injected within a lipid nanoparticle, the mRNA enables cells to produce these proteins, training and activating the immune system against the patient's tumor.

Modernaa CEO Stéphane Bancel stated, "These Phase 3 findings are a milestone for the field of cancer research," emphasizing that personalized mRNA therapy, long dreamed of, has now become a reality. The study's lead researcher, Professor Georgina Long, described the results as "a turning point in melanoma treatment."

The companies plan to present the full data at an upcoming medical conference and then apply for regulatory approval. The treatment could be commercially available next year, and work is ongoing to adapt it for lung, bladder, kidney, and pancreatic cancers.

For Gate users, this development is a striking example of the volatility that scientific advancements in the biotechnology sector create in financial markets. This jump in Moderna's stock price highlights the potential that catalyst events, such as clinical trial results, create in high-risk, high-yield biotechnology stocks. Since such developments can affect not only the stocks involved but also overall market sentiment and risk appetite, it is beneficial for those trading through Gate to closely monitor such macroeconomic and sectoral developments.
DYOR 🔎 NFA ✔️